Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study.

Rituximab is shown to be effective in treating myositis along with corticosteroids as well as a corticosteroid-sparing agent in retrospective studies and open-label clinical trials; however, lack of statistical power should be underlined. Long-term decrease in steroid use and decrease in disease activity markers hint the effective use of rituximab as a glucocorticoid-sparing agent as well as its safety with minimal side effects. Key Points • Long-term decrease in steroid use and decrease in disease activity markers hint the effective use of rituximab as a glucocorticoid-sparing agent as well as its safety with minimal side effects.